Stephens Initiates Twist Bioscience (TWST) With Overweight Rating, Sets $41 PT

Core Insights - Twist Bioscience Corporation (NASDAQ:TWST) is recognized as a leading gene-editing stock by hedge funds, with an Overweight rating and a price target of $41 assigned by analyst Steven Etoch from Stephens [1][2] - The company's DNA synthesis platform, which utilizes silicon chip technology, provides advantages in cost, speed, and scalability, serving markets such as drug discovery, next-generation sequencing (NGS), and synthetic biology [1][4] Financial Performance - Twist has experienced strong revenue growth of 22.7% over the past year, with a five-year compound annual growth rate (CAGR) of 42% [2] - The company is expected to reach adjusted EBITDA break-even by the end of fiscal year 2026 [2] Market Opportunities - NGS is identified as a significant growth opportunity, particularly in applications like liquid biopsy and minimal residual disease (MRD) monitoring [3] - Expansion into adjacent markets is seen as a strategy for strengthening customer relationships [3]